INMB
INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient\'s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio\'s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
INmune Bio Inc. (INMB) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (C).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | C (2.3) | C (2.2) | C (2.4) | C+ (2.6) | C (2.4) |
| 2026-11-05 | C+ (2.5) | C (2.2) | C (2.2) | C+ (2.8) | C+ (2.7) | C (2.5) |
| 2026-10-29 | C+ (2.5) | C (2.2) | C (2.2) | B (3.2) | C+ (2.7) | C+ (2.5) |
| 2026-10-22 | C+ (2.5) | C (2.4) | C (2.2) | B (3.3) | C+ (2.6) | C+ (2.6) |
| 2026-10-15 | C+ (2.5) | C- (2.1) | C (2.2) | B (3.2) | C+ (2.6) | C+ (2.5) |